|
|
Volumn 98, Issue 12, 2006, Pages 810-811
|
|
Researchers may use cancer cell lines to identify target populations prior to clinical trials.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
B RAF KINASE;
BRAF PROTEIN, HUMAN;
ERLOTINIB;
MONOCLONAL ANTIBODY;
NEW DRUG;
QUINAZOLINE DERIVATIVE;
TRASTUZUMAB;
ARTICLE;
CLINICAL TRIAL;
GENETICS;
HUMAN;
METABOLISM;
METHODOLOGY;
NEOPLASM;
PATIENT SELECTION;
TUMOR CELL LINE;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
CELL LINE, TUMOR;
CLINICAL TRIALS;
DRUGS, INVESTIGATIONAL;
HUMANS;
NEOPLASMS;
PATIENT SELECTION;
PROTO-ONCOGENE PROTEINS B-RAF;
QUINAZOLINES;
|
|
EID: 33745330731
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djj271 Document Type: Article |
|
Times cited : (2)
|
|
References (0)
|
